ClinicalTrials.gg
CompletedNCT05040880Updated Feb 16, 2022

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

A Phase 1 interventional study of Telmione plus 80/12.5mg and Micardis plus 80/12.5mg in Hypertension, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 353 studies in Hypertension with a site in Korea, Republic of — 31 open to participants now, 41 under way, 11 of them phase 3. Hypertension · Korea, Republic of.

Enrollment
239th of 304
46 · median 110
Started
2021
with 14 others
Phase 1
102 of 353
6 open now
Registered
263rd of 353
by date

Among the 353 studies in Hypertension with a site in Korea, Republic of, this one is the 239th largest by enrollment of the 304 interventional ones that give a count, is one of 15 that started in 2021, is one of 102 in phase 1, and was the 263rd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

31 of the 353 studies in Hypertension with a site in Korea, Republic of are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Hypertension with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To compare the pharmacokinetics and safety after a single dose administration of Telmione plus® 80/12.5mg and Micardis plus® 80/12.5mg in healthy adult volunteers

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged ≥ 19 years at screening
  • Body weight ≥ 50kg and (BMI) in the range of 18.0 and 30.0 kg/㎡
  • Subjects who do not have congenital or chronic diseases requiring treatment and have no pathological symptoms or findings as a result of physical examination
  • Determined by the investigator to be eligible for study participation based on the results of screening tests (clinical laboratory tests, vital signs, physical examination, 12-lead ) conducted according to the IP characteristics
  • Subjects who decided to participate in the study and signed form voluntarily after receiving detailed explanation of the study and fully understanding

Exclusion criteria

Exclusion Criteria:

  • Subjects with a presence and a history of hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal disease
  • Pregnant(positive urine HCG) or breastfeeding women if female
  • Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  • Subjects with a presence and a history of surgery or gastrointestinal diseases which might significantly change absorption of medicines
  • Subjects with or a history of clinically significant hyper sensitivity to ingredients with IPs, , other drugs including sulfonamide and renin-angiotensin class
  • Subjects with the following results in clinical laboratory tests

    • /ALT/ALP/γ-GTP/ total > UNL (upper normal limit) × 2
    • Creatinine in plasma which is outside the accepted normal range or calculated by MDRD \< 60 mL/min/1.73 ㎡
    • CK > UNL × 2
  • Subjects with a history of drug abuse or positive to drug abuse at urine drug screening test
  • Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or ≤ 90 mmHg, diastolic blood pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or pulse rate (PR) ≤ 40 bpm or ≥ 100 bpm on vital signs measured in sitting position after taking a rest for at least 3 minutes during screening test
  • Subjects with clinically significant opinions including the following results in 12-lead test during screening test

    • > 450 ms
    • PR interval > 200 ms
    • QRS duration > 120 ms
  • Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that can affect drug metabolism
  • Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior to the 1st IP administration, or any over-the-counter (OTC) drug, health functional food or vitamin preparation within 10 days to the 1st IP administration (However, can participate in the study if otherwise eligible in the judgment of the investigator)
  • Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme within 1 month prior to the 1st IP administration
  • Subjects who have participated in any other clinical study or bioequivalnece study within 6 months prior to the 1st IP administration(However, the criterion for termination of participation in other clinical study or bioequivalence study is the last administration date, and the next day is counted as one day.)
  • Subjects who have donated whole blood within 2 months prior to the 1st IP administration or have donated blood components or received transfusion within 1 month prior to the 1st IP administration
  • Subject who have continued drink of alcohol (> 21 units/week, 1 unit = 10 g = 12.5 mL of pure alcohol) within 6 months prior to the 1st IP administration or are unable to stop drinking from the time of signing the form to post study visit

    • alcohol (g) = intake volume(mL) × level(%) × 0.8
  • Subject who have a history of excessive smoking (> 10 cigarettes/day) within 3 months prior to the 1st IP administration and unable to stop smoking from 24 hours before the administration at each period to the last sampling time at each period
  • Subjects who take or are unable to stop foods containing grapefruit from 48 hours before the 1st IP administration to post study visit
  • Subject who take or are unable to stop foods containing caffeine(coffee, green tea, black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the administration at each period to the last sampling time at each period
  • Subjects who have exercised vigorously exceeding the level of daily life during the period from 48 hours before the 1st administration to post study visit, or who are unable to stop vigorous exercise
  • Subjects or their spouse or partner who are not using an approved method of or even if are not planning to become pregnant (e.g., contraceptive administration and implantation, intrauterine device, Those who are not using procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the subject until two weeks after the last bioequivalence study drug administration date
  • Subjects who have determined that the investigator is unsuitable to participate in the bioequivalence test due to reasons other than the above selection/exclusion criteria
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Sequence A

    TRTR

    Drug: Telmione plus 80/12.5mg · Drug: Micardis plus 80/12.5mg

  • Experimental
    Sequence B

    RTRT

    Drug: Telmione plus 80/12.5mg · Drug: Micardis plus 80/12.5mg

Interventions

  • DrugTelmione plus 80/12.5mg

    Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

  • DrugMicardis plus 80/12.5mg

    Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)

06

What researchers measure

Primary outcomes

  1. Cmax of telmisartan

    Time frame: Up to 72 hours

  2. AUClast of telmisartan

    Time frame: Up to 72 hours

  3. Cmax of hydrochlorothiazide

    Time frame: Up to 72 hours

  4. AUClast of hydrochlorothiazide

    Time frame: Up to 72 hours

Secondary outcomes

  1. Tmax of telmisartan

    Time frame: Up to 72 hours

  2. AUCinf of telmisartan

    Time frame: Up to 72 hours

  3. t1/2 of telmisartan

    Time frame: Up to 72 hours

  4. CL/F of telmisartan

    Time frame: Up to 72 hours

  5. Vd/F of telmisartan

    Time frame: Up to 72 hours

  6. Tmax of hydrochlorothiazide

    Time frame: Up to 72 hours

  7. AUCinf of hydrochlorothiazide

    Time frame: Up to 72 hours

  8. t1/2 of hydrochlorothiazide

    Time frame: Up to 72 hours

  9. CL/F of hydrochlorothiazide

    Time frame: Up to 72 hours

  10. Vd/F of hydrochlorothiazide

    Time frame: Up to 72 hours

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, Chungcheongbuk-do 28644, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2021, 3 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Sep 10, 2021
StartActual
Jul 8, 2021
Primary completionActual
Oct 31, 2021
CompletionActual
Oct 31, 2021
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05040880
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Jul 8, 2021
Primary completion
Oct 31, 2021
Completion
Oct 31, 2021
Last update
Feb 16, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion